PD-1 inhibitors, such as pembrolizumab, have achieved significant efficacy in treating a range of malignancies, including NSCLC, melanoma, and hodgkin lymphoma (HL) [120]. This evidence concerns the gene PDCD1 and Hodgkins lymphoma.